RE: No news is good news 👊4 Nov 2023 11:37
Great post from Paternostpauper:
In the current macro environment, it is difficult to identify a potential winner amongst the debris of our markets. There may be an exception.
Valirx is currently at an SP of less than 10p. The SP reached a 2-year low of 5p just over 2 weeks ago, though it has since almost doubled. In Oct ’21, just prior to the VAL201 Letter of Intent with TheorumRX it was 55p. Delays in the deal and subsequent macroeconomic events decimated the SP. However, the company at last appears to be on the verge of finalising the agreement with TRX, led by an enthusiastic CEO who genuinely believes the 201 deal is imminent.
There is much more to Valirx than just 201 though. We have a team of experienced scientists now working from their own new laboratory with access to our own biobank of patient derived cells. This gives far greater control over costs and in-house testing means we are no longer dependent on external bio-lab availability and inevitable delays. We also have developed an amazing portfolio of compounds, any of which could see the current market cap dwarfed. Over the last 2 years we have developed relationships and collaborations with universities both in the UK and abroad.
Our main shareholder is a highly-qualified and experienced scientist, a fellow of the Royal College of Pathologists who is extremely optimistic about the company’s projects and business potential. Formerly of AstraZeneca, now a successful entrepreneur in his own right, Dr Adam Hargreaves is a visiting Professor at the University of Surrey, where he lectures in pharmaceutical toxicology.
Regarding Valirx, in Dr Adam’s own words:
re The position of Valirx in the bio market: ……“look at Companies targeting niche therapy areas, such as Women's Health, and also Oncology - always Oncology. Low MCaps also attractive.”
re Val’s compound portfolio: “Bar the cost of the listing and the lab, there are 5 projects here with a perceived "value" of about 30 pence. Some are very early and some are ready to go. You only need one, and each only needs a 20% chance of success”
re Imagen acquisition: “They’ve bought a business that had an equipment asset value of probably 3+ million; a biobank with significant worth; and all the IP. For 170 grand.
Credit where credit is due. This is an excellent bit of business.”
re Our bio-lab following the acquisition: …..“It's a proper oncology CRO now, with no direct UK competition in this particular space.”
We are indeed very fortunate to have such an eminent scientist as the main shareholder and acting in an advisory capacity both in the commercial and scientific roles.
Sign In
Follow the stocks
